» Articles » PMID: 32508944

Protective Effects of Biscoclaurine Alkaloids on Leukopenia Induced by Co- Radiation

Overview
Date 2020 Jun 9
PMID 32508944
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Leukopenia, a common complication of tumor chemoradiotherapy, contributes serious damage to the hematopoietic, gastrointestinal, and immune systems of the body and can cause delay, discontinuation, or even failure to tumor treatment, thereby greatly threatening human health. The present study aims to investigate the protective effects of biscoclaurine alkaloids (BA) on leukopenia.

Methods: This study was conducted on 60 Kunming mice, which were randomly divided into six groups containing 10 animals each. A hematology analyzer was used to count white blood cells (WBC) in the peripheral blood cell. Mice serum was collected, and the granulocyte-macrophage colony-stimulating factor, vascular cell adhesion molecule 1 (VCAM-1), and interferon- (IFN-) were detected by enzyme-linked immunosorbent assays. Pathological changes were detected through hematoxylin and eosin staining in the liver and spleen of mice. The spleen and liver ultrastructures were observed via electron microscopy.

Results: Results showed that BA ameliorated WBC, PLT reduction in the peripheral blood and significantly increased the levels of IFN- and VCAM-1 in mice serum. BA reduced ionizing radiation-induced injuries to spleen, mitigated the reduction of superoxide dismutase (SOD), and significantly decreased the malonaldehyde (MDA) and xanthine oxidase (XOD) levels in the liver.

Conclusion: BA enhanced the immune and hematopoietic functions and ameliorated the oxidative stress induced by Co- radiation, revealing its therapeutic potential both as a radioprotector and as a radiation mitigator for leukopenia induced by Co- radiation.

Citing Articles

Development and validation of a prognostic nomogram including inflammatory indicators for overall survival in hepatocellular carcinoma patients treated primarily with surgery or loco-regional therapy: A single-center retrospective study.

Wang X, Xu J, Jia Z, Sun G Medicine (Baltimore). 2024; 103(50):e40889.

PMID: 39686498 PMC: 11651482. DOI: 10.1097/MD.0000000000040889.


Exploring the effects of Qijiao Shengbai capsule on leukopenic mice from the perspective of intestinbased on metabolomics and 16S rRNA sequencing.

Cao Y, Zhang S, Tang L, Chen Y, Jiang S, Liu L Heliyon. 2023; 9(9):e19949.

PMID: 37810141 PMC: 10559567. DOI: 10.1016/j.heliyon.2023.e19949.


Amelioration of radiation-induced liver damage by -coumaric acid in mice.

Li Y, Wu J, He Q, Gu J, Zhang L, Niu H Food Sci Biotechnol. 2022; 31(10):1315-1323.

PMID: 35992325 PMC: 9385927. DOI: 10.1007/s10068-022-01118-8.


The Involvement of Macrophage Colony Stimulating Factor on Protein Hydrolysate Injection Mediated Hematopoietic Function Improvement.

Wang S, Zhang Y, Meng W, Dong Y, Zhang S, Teng L Cells. 2021; 10(10).

PMID: 34685756 PMC: 8534652. DOI: 10.3390/cells10102776.

References
1.
Molla M, Gironella M, Miquel R, Tovar V, Engel P, Biete A . Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. Int J Radiat Oncol Biol Phys. 2003; 57(1):264-73. DOI: 10.1016/s0360-3016(03)00523-6. View

2.
Gao S, Li X, Ding X, Qi W, Yang Q . Cepharanthine Induces Autophagy, Apoptosis and Cell Cycle Arrest in Breast Cancer Cells. Cell Physiol Biochem. 2017; 41(4):1633-1648. DOI: 10.1159/000471234. View

3.
Geric M, Gajski G, Mihaljevic B, Miljanic S, Domijan A, Garaj-Vrhovac V . Radioprotective properties of food colorant sodium copper chlorophyllin on human peripheral blood cells in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2019; 845:403027. DOI: 10.1016/j.mrgentox.2019.02.008. View

4.
Nakaoji K, Nayeshiro H, Tanahashi T, Su Y, Nagakura N . Bisbenzylisoquinoline alkaloids from Stephania cepharantha and their effects on proliferation of cultured cells from the murine hair apparatus. Planta Med. 1997; 63(5):425-8. DOI: 10.1055/s-2006-957726. View

5.
Singh V, Seed T . A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. Int J Radiat Biol. 2017; 93(9):851-869. DOI: 10.1080/09553002.2017.1332438. View